Current therapy for hepatitis C. (Q36263113)

From Wikidata

Jump to navigation Jump to search

scientific article

edit

Language	Label	Description	Also known as
English	Current therapy for hepatitis C.	scientific article

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16175369

retrieved

13 August 2017

review article

1 reference

stated in

Europe PubMed Central

title

Current therapy for hepatitis C. (English)

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16175369

retrieved

13 August 2017

author

Mireen Friedrich-Rust

series ordinal

1

object named as

Mireen Friedrich-Rust

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16175369

retrieved

13 August 2017

Stefan Zeuzem

series ordinal

2

object named as

Stefan Zeuzem

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16175369

retrieved

13 August 2017

author name string

Christoph Sarrazin

series ordinal

3

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16175369

retrieved

13 August 2017

publication date

21 September 2005

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16175369

retrieved

13 August 2017

published in

International Journal of Colorectal Disease

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16175369

retrieved

13 August 2017

volume

22

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16175369

retrieved

13 August 2017

issue

4

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16175369

retrieved

13 August 2017

page(s)

341-349

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16175369

retrieved

13 August 2017

cites work

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS00384-005-0038-9

retrieved

21 January 2018

Optimized virologic response in hepatitis C virus genotype 4 with peginterferon-alpha2a and ribavirin

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS00384-005-0038-9

retrieved

21 January 2018

Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/16175369

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Criteria for the definition of acute and chronic hepatitis C]

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/16175369

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Standardization of hepatitis C virus RNA quantification

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/16175369

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Detection of residual hepatitis C virus RNA by transcription-mediated amplification in patients with complete virologic response according to polymerase chain reaction-based assays

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/16175369

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/16175369

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/16175369

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/16175369

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Standard treatment of acute and chronic hepatitis C]

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/16175369

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/16175369

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Diagnosis, progression and therapy of hepatitis C virus infection as well as viral infection in children and adolescents--results of an evidenced based consensus conference of the German Society for Alimentary Metabolic Disorders and and in coopera

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/16175369

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Highly sensitive hepatitis C virus RNA detection assays for decision of treatment (dis)continuation in patients with chronic hepatitis C.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/16175369

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C 2002 (June 10-12, 2002)

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/16175369

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pegylated interferon-alpha 2b-ribavirin combination in Egyptian patients with genotype 4 chronic hepatitis

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/16175369

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/16175369

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/16175369

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/16175369

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Therapy of acute hepatitis C.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/16175369

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/16175369

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Quantitation of hepatitis C virus RNA by third generation branched DNA-based signal amplification assay

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/16175369

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/16175369

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002--June 10-12, 2002.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/16175369

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of acute hepatitis C with interferon alfa-2b

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/16175369

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Is an "a la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/16175369

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics of peginterferons

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/16175369

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Triple therapy with amantadine in treatment-naive patients with chronic hepatitis C: a placebo-controlled trial

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/16175369

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Development and pharmacokinetics and pharmacodynamics of pegylated interferon alfa-2a (40 kD).

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/16175369

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/16175369

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/16175369

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/16175369

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/16175369

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/16175369

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Twelve weeks of follow-up is sufficient for the determination of sustained virologic response in patients treated with interferon alpha for chronic hepatitis C.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/16175369

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of chronic non-A,non-B hepatitis with recombinant human alpha interferon. A preliminary report

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/16175369

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High rate of spontaneous clearance of acute hepatitis C virus genotype 3 infection

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/16175369

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Peginterferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/16175369

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy of a 24-week course of PEG-interferon alpha-2b monotherapy in patients with acute hepatitis C after failure of spontaneous clearance.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/16175369

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/16175369

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/16175369

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/16175369

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/16175369

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prophylactic SSRI during interferon alpha re-therapy in patients with chronic hepatitis C and a history of interferon-induced depression

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/16175369

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

DOI

10.1007/S00384-005-0038-9

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16175369

retrieved

13 August 2017

PubMed publication ID

16175369

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16175369

retrieved

13 August 2017

 

Sitelinks

Wikipedia(0 entries)

edit

Wikibooks(0 entries)

edit

Wikinews(0 entries)

edit

Wikiquote(0 entries)

edit

Wikisource(0 entries)

edit

Wikiversity(0 entries)

edit

Wikivoyage(0 entries)

edit

Wiktionary(0 entries)

edit

Multilingual sites(0 entries)

edit

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36263113&oldid=2198485298"